To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease all over the world (1). In early 2020, a new definition of MAFLD has been proposed and is becoming increasingly widely accepted. The new diagnostic criteria are based on the histology or imaging of liver biopsies, or even blood biomarker tests indicative of the presence of fatty liver while satisfying any one of the following three conditions: overweight/obesity, type 2 diabetes, or metabolic dysfunction (2). The information on the prevalence of MAFLD is scarce. This study is designed to conduct MAFLD screening in adults with health check-ups at multiple health examination centers across China. The primary objective is to investigate the prevalence of MAFLD among adults in China.
Study Type
OBSERVATIONAL
Enrollment
2,000
Fibrotouch will be performed showing the stiffness and fat content of liver
Bejing Tsinghua Chang Gung Hospital
Beijing, Bejing, China
RECRUITINGTo investigate the prevalence of MAFLD among adults at multiple health examination centers across China.
MAFLD means metabolic dysfunction-associated fatty liver disease
Time frame: through study completion, an average of 1 year
To assess the proportion of overweight or obese patients with MAFLD (BMI≥23 kg/m²).
MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index
Time frame: through study completion, an average of 1 year
To assess the prevalence of metabolic dysfunction among patients with MAFLD who are lean or normal in body weight (BMI < 23 kg/m²)
MAFLD means metabolic dysfunction-associated fatty liver disease; BMI means body mass index
Time frame: through study completion, an average of 1 year
To assess the prevalence of type 2 diabetes among patients with MAFLD.
MAFLD means metabolic dysfunction-associated fatty liver disease
Time frame: through study completion, an average of 1 year
To assess the prevalence of liver fibrosis and cirrhosis among patients with MAFLD.
MAFLD means metabolic dysfunction-associated fatty liver disease
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.